In vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022)
In vitro Activity of Gepotidacin Tested Against Molecularly Characterized <i>Escherichia coli</i> Isolates Responsible for Urinary Tract Infections in the US (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1060
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1081
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022)
<i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1059
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022)
<i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1061
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from the United States during 2019–2022
<i>In vitro</i> Activity of Gepotidacin and Comparator Agents Against a Collection of <i>Klebsiella pneumoniae</i> Urine Isolates Collected from the United States during 2019–2022. Lead author: S. J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1062
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023)
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1080
Antimicrobial Susceptibility of Enterobacterales Causing Infection in the Elderly: Focus on Aztreonam-Avibactam and Recently Approved β-Lactamase Inhibitor Combinations
Antimicrobial Susceptibility of Enterobacterales Causing Infection in the Elderly: Focus on Aztreonam-Avibactam and Recently Approved β-Lactamase Inhibitor
Combinations. Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1082
Antimicrobial Activity of Aztreonam- Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in United States Medical Centers (2019–2023). Lead author: Timothy B. Doyle, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1083
Antimicrobial Activity of Aztreonam- Avibactam and Other β-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1084
Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of aztreonam-avibactam and comparator agents (2019–2023)
Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of aztreonam-avibactam and comparator agents (2019–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1085
Activity of rezafungin against clinical isolates of uncommon species of Candida spp.
Activity of rezafungin against clinical isolates of uncommon species of <i>Candida</i> spp. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1095
Activity of Ibrexafungerp and Comparator Antifungals Tested Against Candida and Aspergillus Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023
Activity of Ibrexafungerp and Comparator Antifungals Tested Against <i>Candida</i> and <i>Aspergillus</i> Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1096
Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program
Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1168
Occurrence of β-lactamases among Enterobacterales isolates from United States Hospitals in a 10-year period: Report from the International Network for Optimal Resistance Monitoring (INFORM) Program
Occurrence of β-lactamases among Enterobacterales isolates from United States Hospitals in a 10-year period: Report from the International Network for Optimal Resistance Monitoring (INFORM) Program. Lead author: Mariana Castanheira, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1351
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-Resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-Resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1360
Cefiderocol Activity against Pseudomonas aeruginosa, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023)
Cefiderocol Activity against <i>Pseudomonas aeruginosa</i>, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1361
Cefiderocol Activity against Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Cefiderocol Activity against Carbapenem-Resistant <i>Acinetobacter baumannii-calcoaceticus</i> Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1362
Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023)
Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1363
Cefiderocol Activity against Pseudomonas aeruginosa Clinical Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023)
Cefiderocol Activity against <i>Pseudomonas aeruginosa</i> Clinical Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1364
In vitro Activity of Ceftobiprole Against Prominent Methicillin-resistant Staphylococcus aureus Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program
<i>In vitro</i> Activity of Ceftobiprole Against Prominent Methicillin-resistant <i>Staphylococcus aureus</i> Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program. Lead author: John H. Kimbrough, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1526
Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020)
Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020). Lead author: Joshua M. Maher, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1527
In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020
<i>In vitro</i> activity of omadacycline and comparator agents against a collection of <i>Neisseria gonorrhoeae</i> urine isolates collected from the United States during 2018-2020. Lead author: S.J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1528
Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023)
Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023). Lead author: Michael D. Huband, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P411
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western and Eastern Europe (SENTRY Program; 2021–2022)
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalised with Bacterial Pneumonia in Western and Eastern Europe (SENTRY Program; 2021–2022). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #3220
Activity of gepotidacin against Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022).
Activity of gepotidacin against <i>Klebsiella pneumoniae<i>, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2019–2022). Lean Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1441
Activity of aztreonam-avibactam and comparator agents against a global collection of metallo-β-lactamase-producing Enterobacterales
Activity of aztreonam-avibactam and comparator agents against a global collection of metallo-β-lactamase-producing Enterobacterales. Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1439
β-lactam resistance mechanisms in baseline Enterobacterales from the REVISIT and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials
β-lactam resistance mechanisms in baseline Enterobacterales from the REVISIT and ASSEMBLE aztreonam-avibactam Phase 3 clinical trials. Lead Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1824
High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in Morganella morganii
High-level plazomicin exposure selects for mutations in fusA, ratA, and a novel two-component system in <i>Morganella morganii</i>. Lead Author: John H. Kimbrough, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1694
Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterized clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem non-susceptible Enterobacterales, including molecularly characterized clinical isolates causing infection in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P1406
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in Europe, Asia, and Latin America (2018–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in Europe, Asia, and Latin America (2018–2023). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1357
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from Europe during 2019–2022
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of <i>Klebsiella pneumoniae</i> Urine Isolates Collected from Europe during 2019–2022. Presenting Author: S. J. Ryan Arends, Ph.D., at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #2433
Use of Voriconazole to Predict Susceptibility and Resistance to Isavuconazole for Aspergillus fumigatus by Using the CLSI Methods and Interpretive Criteria
Use of Voriconazole to Predict Susceptibility and Resistance to Isavuconazole for <i>Aspergillus fumigatus</i> by Using the CLSI Methods and Interpretive Criteria. Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #2930
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By Escherichia coli and Staphylococcus saprophyticus Collected in Europe in 2022
Analysis of Resistance to Oral Standard-of-Care Antibiotics for Urinary Tract Infections Caused By <i>Escherichia coli</i> and <i>Staphylococcus saprophyticus</i> Collected in Europe in 2022. Presenting Author: S. J. Ryan Arends at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV11-06
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem-resistant <i>Acinetobacter baumannii-calcoaceticus</i> complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV0604
Rezafungin Activity Against Echinocandin–Nonwildtype Candida glabrata Clinical Isolates Collected in European countries (2014–2021)
Rezafungin Activity Against Echinocandin–Nonwildtype <i>Candida glabrata</i> Clinical Isolates Collected in European countries (2014–2021). Lead Author: Mariana Castanheira, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Activity of cefiderocol against carbapenem non-susceptible Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022)
Activity of cefiderocol against carbapenem non-susceptible <i>Pseudomonas aeruginosa</i>, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2022). Lead Author: Rodrigo Mendes, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #MTV0605
Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019–2022)
Activity of gepotidacin against molecularly characterized Klebsiella pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2019–2022). Lead Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P2479
Proposed zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 2 criteria
Proposed zosurabalpin broth microdilution quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 2 criteria. Lead Author: Michael Huband, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #P2452
Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE- 2/EAGLE-3 clinical trials for uncomplicated urinary tract infections
Genetic relationship and mechanisms contributing to reduced gepotidacin susceptibility in isolates from EAGLE-2/EAGLE-3 clinical trials for uncomplicated urinary tract infections. Presenting Author: Rodrigo Mendes at ECCMID, 27-30 April 2024, Barcelona, Spain
Poster #1052
Bloodstream Infections in European Hospitals: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2021–2022)
Bloodstream Infections in European Hospitals: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2021–2022). Lead Author: Helio S. Sader, presented at ECCMID, 27-30 April 2024, Barcelona, Spain
In Vitro Antimicrobial Activity of Taurolidine against Associated with Catheter-Related Bloodstream Infections
In Vitro Antimicrobial Activity of Taurolidine against Associated with Catheter-Related Bloodstream Infections. Lead authors: Jared L. Crandon, PharmD presented at SHEA Spring Conference 2024 Houston, TX
Poster #130
Trend Analysis of Oritavancin and Comparator Agents’ Activities against Enterococcus species Causing Infections in US Medical Centers between 2017–2019 and 2022
Trend Analysis of Oritavancin and Comparator Agents’ Activities against Enterococcus species Causing Infections in US Medical Centers between 2017–2019 and 2022. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #734
Activity of Sulbactam-Durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates
Activity of Sulbactam-Durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates. Lead author: MD Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2517
Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints
Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints. Lead author: Helio S. Sader, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2801
Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis. Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2785
Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021). Lead author: Mariana Castanheira, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2756
Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
Delafloxacin and Comparator Fluoroquinolones In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022). Lead author: Michael D. Huband, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2754
Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program. Lead author: Cecilia G. Carvalhaes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2115
High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021)
High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021). Lead author: Lalitagauri M. Deshpande, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2139
In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources
In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources. Lead author: Antony Pfaffle, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.
Poster #2117
